R
Robert M. DiPardo
Researcher at United States Military Academy
Publications - 61
Citations - 3403
Robert M. DiPardo is an academic researcher from United States Military Academy. The author has contributed to research in topics: Cholecystokinin & Receptor. The author has an hindex of 21, co-authored 61 publications receiving 3268 citations. Previous affiliations of Robert M. DiPardo include Merck & Co..
Papers
More filters
Journal ArticleDOI
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
Ben E. Evans,Kenneth E. Rittle,Mark G. Bock,Robert M. DiPardo,Roger M. Freidinger,W. L. Whitter,George F. Lundell,Daniel F. Veber,Paul S. Anderson,Raymond S.L. Chang,Victor J. Lotti,D. J. Cerino,Tsing-Bau Chen,Paul J. Kling,K. A. Kunkel,James P. Springer,J. Hirshfield +16 more
TL;DR: 3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.
Journal ArticleDOI
Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin
Ben E. Evans,Mark G. Bock,Kenneth E. Rittle,Robert M. DiPardo,Willie L. Whitter,Daniel F. Veber,Paul S. Anderson,Roger M. Freidinger +7 more
TL;DR: The design and synthesis of nonpeptidal antagonists of the peptide hormone cholecystokinin are described, and several of these compounds have high specificity and nanomolar binding affinity and are active after oral administration.
Journal ArticleDOI
Benzodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260
Mark G. Bock,Robert M. DiPardo,Ben E. Evans,Kenneth E. Rittle,Willie L. Whitter,Daniel F. Veber,Paul S. Anderson,Roger M. Freidinger +7 more
Journal ArticleDOI
Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists.
Ben E. Evans,Kenneth E. Rittle,Mark G. Bock,Robert M. DiPardo,Roger M. Freidinger,W. L. Whitter,George F. Lundell,Daniel F. Veber,Paul S. Anderson,Raymond S.L. Chang,Victor J. Lotti,D. J. Cerino,Tsing-Bau Chen,Paul J. Kling,K. A. Kunkel,James P. Springer,J. Hirshfield +16 more
TL;DR: In this article, 3.3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described.
Journal ArticleDOI
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists
B. E. Evans,Kenneth E. Rittle,Mark G. Bock,Robert M. DiPardo,Roger M. Freidinger,Willie L. Whitter,N. P. Gould,George F. Lundell,Carl F. Homnick +8 more
TL;DR: A series of 3-substituted 5-phenyl-1,4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin, serve to illuminate the distinction between central and peripheral CCK receptors, as well as to provide orally effective CCK antagonists of potential pharmacological or therapeutic utility.